Literature DB >> 18094657

Orthopedic surgery options for the treatment of primary osteosarcoma.

German A Marulanda1, Eric R Henderson, David A Johnson, G Douglas Letson, David Cheong.   

Abstract

BACKGROUND: Osteosarcoma is the most common malignant primary neoplasm of bone. Orthopedic procedures are essential components in the multidisciplinary treatment of osteosarcoma. Limb-salvaging procedures offer adequate disease control comparable to the results obtained by amputations. This review discusses the advantages and disadvantages of the various types of amputations and the limb-salvaging techniques for the treatment of osteosarcoma.
METHODS: The authors analyzed the characteristics of limb-salvaging procedures and amputations for osteosarcoma. Qualitative and quantitative studies published in the English language that are listed in the National Library of Medicine were used as the basis for this review. In addition, a review of an expandable prosthesis is included.
RESULTS: Limb-salvaging techniques have acceptable rates of disease control. However, amputation remains a valid procedure in selected cases of osteosarcoma in most parts of the world. Orthopedic oncology surgeons have various materials, procedures, and techniques available to achieve disease control and improve function in patients with osteosarcoma.
CONCLUSIONS: The surgical management of patients with osteosarcoma is challenging. No difference in survival has been shown between amputations and adequately performed limb-salvaging procedures. Optimal tumor resection and a functional residual limb with increased patient survival are the goals of modern orthopedic oncology.

Entities:  

Mesh:

Year:  2008        PMID: 18094657     DOI: 10.1177/107327480801500103

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  39 in total

Review 1.  The trends and challenges in orthopaedic simulation.

Authors:  Mohamed Mediouni; Alexander Volosnikov
Journal:  J Orthop       Date:  2015-06-19

2.  Selective effects of hydroxyapatite nanoparticles on osteosarcoma cells and osteoblasts.

Authors:  Fangzhu Qing; Zhe Wang; Youliang Hong; Ming Liu; Bo Guo; Hongrong Luo; Xingdong Zhang
Journal:  J Mater Sci Mater Med       Date:  2012-08-19       Impact factor: 3.896

3.  Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.

Authors:  Venugopal Thayanithy; Aaron L Sarver; Reena V Kartha; Lihua Li; Andrea Y Angstadt; Matthew Breen; Clifford J Steer; Jaime F Modiano; Subbaya Subramanian
Journal:  Bone       Date:  2011-10-18       Impact factor: 4.398

4.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

5.  Chondroblastic osteosarcoma secondary to fibrosarcoma: A case report and literature review.

Authors:  Yi-Fei Zheng; Jun Lin; Hui-Lin Yang
Journal:  Oncol Lett       Date:  2015-10-12       Impact factor: 2.967

6.  Evaluation of three-dimensional arterial spin labeling perfusion imaging for the pathological investigation of musculoskeletal tumors.

Authors:  Lingbin Xu; Leiming Xu; Haidong Zhu
Journal:  Exp Ther Med       Date:  2018-04-03       Impact factor: 2.447

7.  The role of mechano-growth factor E peptide in the regulation of osteosarcoma.

Authors:  Jin Shang; Xin Fan; Huan Liu
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

8.  Minnelide reduces tumor burden in preclinical models of osteosarcoma.

Authors:  Sulagna Banerjee; Venugopal Thayanithy; Veena Sangwan; Tiffany N Mackenzie; Ashok K Saluja; Subbaya Subramanian
Journal:  Cancer Lett       Date:  2013-03-14       Impact factor: 8.679

9.  MiR-34c inhibits osteosarcoma metastasis and chemoresistance.

Authors:  Meng Xu; Hua Jin; Cheng-Xiong Xu; Wen-Zhi Bi; Yan Wang
Journal:  Med Oncol       Date:  2014-05-07       Impact factor: 3.064

10.  Limb salvage surgery in bone tumors: a retrospective study of 50 cases in a single center.

Authors:  Ashutosh Chauhan; G R Joshi; B K Chopra; Manomoy Ganguly; G R Reddy
Journal:  Indian J Surg Oncol       Date:  2013-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.